In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors

Molecular Immunology

Volumn 63, Issue 2, 2015, Pages 320-327

  Lobaina, Yadira ^a   Hardtke, Svenja ^b   Wedemeyer, Heiner ^b   Aguilar, Julio Cesar ^a   Schlaphoff, Verena ^b  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

B cells; HBV; Nasvac; Therapeutic vaccine

Indexed keywords

CD40 LIGAND; CD86 ANTIGEN; HEPATITIS B CORE ANTIGEN; HEPATITIS B VACCINE; NASVAC VACCINE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FLOW CYTOMETRY; HEPATITIS B; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; CELL PROLIFERATION; CYTOLOGY; DONOR; FEMALE; HEPATITIS B VIRUS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; T LYMPHOCYTE;

HEPATITIS B VIRUS;

B-LYMPHOCYTES; BIOLOGICAL MARKERS; CELL PROLIFERATION; FEMALE; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LYMPHOCYTE ACTIVATION; MALE; T-LYMPHOCYTES; TISSUE DONORS;

EID: 84912010867     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.08.003     Document Type: Article

References (30)

1. Abbas A.K., Lichtman A.H., Pillai S. Cellular and Molecular Immunology 2012, Elsevier Saunders, Hannover. 7th edition.
2. Aguilar J., Lobaina Y., Muzio V., Garcia D., Penton E., Iglesias E., et al. Development of a nasal vaccine for chronic hepatitis infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol. Cell Biol. 2004, 82:539-546.
3. Aguilar-Betancourt A., González C.A., Cinza Z., Cabrera J., Veliz G., Moreno S.R., et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int. J. Infect. Dis. 2007, 11:394-401.
4. Akbar S.M., Yoshida O., Chen S., Aguilar J.C., Abe M., et al. Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection. Antiviral Ther. 2010, 15:887-895.
5. Akbar S.M., Al-Mahtab M., Rahman S., Aguilar J.C., Hiasa Y., Mishiro S. A phase III clinical trial with a therapeutic vaccine containing both HBsAg and HBcAg administered via both mucosal and parenteral routes in patients with chronic hepatitis B. Hepatology 2013, 58(S1):647A-705A.
6. Al-Mahtab M., Akbar S.M., Aguilar J.C., Uddin H., Khan S.I., Rahman S. Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B. Hepatol. Int. 2013, 7:981-989.
7. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.
8. Crawford A., Macleod M., Schumacher T., Corlett L., Gray D. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J. Immunol. 2006, 176:3498-3506.
9. Engel P., Gribben J.G., Freeman G.J., Zhou L.J., Nozawa Y., et al. The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. Blood 1994, 84(5):1402-1407.
10. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142(6):1264-1273.
11. Freeman G.J., Long A.J., Iwai Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000, 192:1027-1034.
12. Freeman G.J., Wherry E.J., Ahmed R., et al. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 2006, 203:2223-2227.
13. Inchauspe G., Michel M.L. Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. J. Viral Hepat. 2007, 14(1):97-103.
14. Lazdina U., Cao T., Steinbergs J., Alheim M., Pumpens P., Peterson D.L., et al. Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells. J. Virol. 2001, 75(14):6367-6374.
15. Lazdina U., Alheim M., Nystrom J., Hultgren C., Borisova G., Sominskaya I., et al. Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. J. Gen. Virol. 2003, 84:139-146.
16. Lobaina Y., Trujillo H., Garcia D., Gambe A., Chacon Y., Blanco A., et al. The effect of the parenteral route of administration on the immune response to simultaneous nasal-parenteral immunizations using a new HBV therapeutic vaccine candidate. Viral Immunol. 2010, 23(5):521-529.
17. Michel M.L., Mancini-Bourgine M. Therapeutic vaccination against chronic hepatitis B virus infection. J. Clin. Virol. 2005, 34(1):S108-S114.
18. Milich D., Chen M., Schodel F., Peterson D.L., Jones J.E., Hughes J.L. Role of B cells in antigen presentation of the hepatitis B core. Procedia Natl. Acad. Sci. 1997, 94:14648-14653.
19. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat. Rev. Immunol. 2002, 2:957-964.
20. Negri D.M.R., Pinto D., Vendetti S., et al. Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytes. Infect. Immun. 2009, 77(5):1924-1935.
21. Oliviero B., Varchetta S., Paudice E., Michelone G., Zaramella M., et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009, 137:1151-1160.
22. Oliviero B., Cerino A., Varchetta S., Paudice E., Pai S., et al. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. J. Hepatol. 2011, 55:53-60.
23. Op den Brouw M.L., Binda R.S., et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 2008, 126:280-289.
24. Riedl P., Stober D., Oehninger C., Melber K., Reimann J., Schirmbeck R. Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J. Immunol. 2002, 168:4951-4959.
25. Rodriguez-Pinto D., Moreno J. B cells can prime naive CD4+ T cells in vivo in the absence of other professional antigen-presenting cells in a CD154-CD40-dependent manner. Eur. J. Immunol. 2005, 35:1097-1105.
26. Scheerlinck J.P., Burssens G., Brys L., Michel A., Hauser P., De Baetselier P. Differential presentation of hepatitis B S-preS(2) particles and peptides by macrophages and B-cell like antigen-presenting cells. Immunology 1991, 73(1):88-94.
27. Scott-Algara D., Mancini-Bourgine M., Fontaine H., Pol S., Michel M.L. Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination. PLoS ONE 2010, 5(1):8761.
28. Smith V.E., et al. The search for cost-effective treatment of chronic hepatitis B. JMCP 2008, 14(1):61-64.
29. Vanlandschoot P., Van Houtte F., et al. LPS-binding protein and CD14-dependent attachment of hepatitis B surface antigen to monocytes is determined by the phospholipid moiety of the particles. J. Gen. Virol. 2002, 83:2279-2289.
30. Vanlandschoot P., Cao T., Leroux-Roels G. The nucleocapsid of the hepatitis B virus: a remarkable immunogenic structure. Antiviral Res. 2003, 60:67-74.